# Wilcoxon test

Also found in: Medical, Acronyms, Wikipedia.

## Wilcoxon test

(wɪlˈkɒksən)
n
(Statistics)
a. Also called: Wilcoxon matched-pairs signed-ranks test a statistical test for the relative size of the scores of the same or matched subjects under two experimental conditions by comparing the distributions for positive and negative differences of the ranks of their absolute values
b. Wilcoxon Mann-Whitney test See Mann-Whitney test
[named after Frank Wilcoxon (1892–1965), Irish mathematician and statistician]
Collins English Dictionary – Complete and Unabridged, 12th Edition 2014 © HarperCollins Publishers 1991, 1994, 1998, 2000, 2003, 2006, 2007, 2009, 2011, 2014
Mentioned in ?
References in periodicals archive ?
The non-parametric Wilcoxon test was used to test for statistical significance (p=0.0001, n=12).
Table 1 shows descriptive statistics (median and interquartile range) and Wilcoxon test results for the comparison of adolescents' accelerometer-measured PA and sedentary behavior during the whole day between HCA and non-HCA days.
The Wilcoxon test results in Table 3 reveal a significant difference between CP1 and the other three settings; hence, the performance of the concave-type search curve was excellent.
Responsiveness of the ROE-T to changes in RP outcomes Preoperative Postoperative p Mean [+ or -] Median Mean [+ or -] Median standard standard deviation deviation ROE-T Question 1 0.3[+ or -]0.5 0.0 3.6[+ or -]0.6 4.0 0.0001 (w) Question 2 0.6[+ or -]1.1 0.0 3.6[+ or -]0.6 4.0 0.0001 (w) Question 3 0.6[+ or -]0.8 0.0 3.4[+ or -]0.8 4.0 0.0001 (w) Question 4 1.4[+ or -]1.0 1.5 4.0[+ or -]0.2 4.0 0.0001 (w) Question 5 0.4[+ or -]0.6 0.0 3.6[+ or -]1.0 4.0 0.0001 (w) Question 6 0.1[+ or -]0.3 0.0 4.0[+ or -]0.0 4.0 0.0001 (w) Total 3.3[+ or -]2.3 3.0 22.2[+ or -]2.8 23.0 0.0001 (w) scores ROE-T: Rhinoplasty Outcome Evaluation-Turkish; RP: rhinoplasy; (w) : Wilcoxon test TABLE 3.
The relationship between the participants' age distribution and IOP in different body positions was examined using Spearman's correlation test (Table 3) and the relationship between sex and IOP in different body positions was examined using the Wilcoxon test (Table 4).
Comparison of pre-treatment urine 5-hydroxyindoleacetic acid /creatinine levels and those at the end of biofeedback therapy (6th month in completed the study) n (a) Mean (b) SD p (c) Baseline 45 6.249 4.132 u5-HIAA/Cr At the end of 0.951 biofeedback 45 6.190 4.715 therapy (6th month) u5-HIAA/Cr: Urinary 5-hydroxyindole acetic acid, SD: Standard deviation (a): The number of patients who completed the study (b): Urine 5-hydroxyindoleacetic acid/creatinine (mg/g creatinine) (c): Wilcoxon test Table 4.
Across sampling schemes only UCO showed significant bottlenecks under the Wilcoxon test; East Arcadia showed a significant Wilcoxon value for the historical allele frequency sampling.
of variation Initial 41.90 0.12 43.0 33.50 48.20 9.7% Final 42.81 43.1 34.00 48.30 9.4% Test WILCOXON TEST Effect Z P Size Initial -2.58 0.010 0.58 Final INTERPRETATION OF RESULTS
Within a given attractant trap, significantly more males than females were trapped by sticky spheres (Wilcoxon test: Z = -2.023; P = 0.043; n = 5; Fig.
The Wilcoxon test revealed no significant differences between these equations in estimating the GFR (P=0.22).
Median age was compared by Wilcoxon test. The proportion of infections in clusters was lowest for the fifth epidemic; the proportion of infections in clusters per epidemic differed significantly during 2013-2017 ([chi square] = 11.30; p = 0.023).
CDI recurrence Days until CDI within 90 days after recurrence, FMT, n (%) median (range) All subjects Normal zinc (n = 49) 3 (6.12) 72 (6-88) Low zinc (n = 31) 5 (16.13) 15 (4-81) Total (n = 80) 8 (10.00) 28 (4-88) p value 0.097 0.456 Test utilized Wilcoxon test Mann-Whitney U Low zinc subjects Not supplemented 3 (50.00) 14 (4-81) (n = 6) Supplemented 2 (8.00) 28 (15-41) (n = 25) Total (n = 31) 5 (16.13) 15 (4-81) p value 0.014 0.564 Test utilized Wilcoxon test Mann-Whitney U CDI, Clostridium difficile infection.

Site: Follow: Share:
Open / Close